Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 1071 to 1080 of 1090 total matches.
Budesonide (Entocort EC) For Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002 (Issue 1122)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Budesonide (Entocort EC AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19), has been approved for oral treatment of mild to moderate active Crohn's disease involving the ileum and/or ascending colon. Both oral budesonide and budesonide enemas have been available for years in Europe and Canada for treatment of inflammatory bowel disease.
Zolmitriptan (Zomig) Nasal Spray for Migraine
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004 (Issue 1174)
cholesterol or a family history of coronary artery disease.
INTERACTIONS — The drug should not be used within ...
Zolmitriptan (Zomig - AstraZeneca) nasal spray was recently approved by the FDA for treatment of migraine. It is the second selective serotonin receptor agonist ("triptan") to become available as a nasal spray; sumatriptan has been available in this form since 1997. Some patients with migraine cannot take tablets because of nausea and vomiting, and nasal sprays are more convenient than subcutaneous injections.
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022 (Issue 1641)
Table 1). They are the first
drugs to be authorized by the FDA for this indication.1
Two other pairs ...
The FDA has issued an Emergency Use Authorization
(EUA) for the investigational long-acting monoclonal
antibodies tixagevimab and cilgavimab (Evusheld –
AstraZeneca) to be administered concomitantly by IM
injection for pre-exposure prophylaxis of COVID-19 in
persons ≥12 years old who weigh ≥40 kg and have
either a history of severe allergy that prevents their
vaccination against COVID-19 or moderate or severe
immune compromise (see Table 1). They are the first
drugs to be authorized by the FDA for this indication.
Two other pairs of antibodies, bamlanivimab plus
etesevimab...
Chemotherapy for Esophageal, Gastric and Colorectal Cancers
Treatment Guidelines from The Medical Letter • Aug 01, 2006 (Issue 48)
of Cornell University
EDITOR, DRUG INFORMATION: Jean-Marie Pflomm, Pharm.D. ADVISORY BOARD: Jules Hirsch ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Ofloxacin
The Medical Letter on Drugs and Therapeutics • Jul 26, 1991 (Issue 849)
with ofloxacin Interactions drug ...
Ofloxacin (Floxin - McNeil, Ortho), a new fluoroquinolone antibacterial agent, was recently marketed in the USA for oral treatment of various infections caused by susceptible microorganisms. Ofloxacin is the third fluoroquinolone to become available in this country. Norfloxacin (Noroxin - Medical Letter, 29:25, 1987) is marketed only for treatment of urinary tract infections. Ciprofloxacin (Cipro - Medical Letter, 30:11, 1988), like ofloxacin, is approved for use in a variety of infections.
Apomorphine (Apokyn) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005 (Issue 1200)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 47 (Issue 1200)
January 17, 2005 ...
Apomorphine (Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with advanced Parkinson's disease. It has been available in Europe for many years.
Salmeterol
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994 (Issue 921)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Salmeterol xinafoate (Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.
Sildenafil for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004 (Issue 1177)
as Viagra for treatment
of erectile dysfunction (Medical Letter 1998; 40:51).
DRUG THERAPY FOR PAH ...
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction (Medical Letter 1998; 40:51).
Immune Globulin IV for Prevention of RH Isoimmunization and for Treatment of ITP
The Medical Letter on Drugs and Therapeutics • Jan 19, 1996 (Issue 966)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
immune globulin (human) has been available for many years in an intramuscular (IM) formulation for prevention of Rh isoimmunization in pregnant Rh-negative women (Medical Letter, 16:3, 1974). Recently, the US Food and Drug Administration (FDA) approved the first intravenous (IV) immune globulin preparation (WinRho SD - Univax), not only for preventing Rh isoimmunization, but also for treatment of immune thrombocytopenic purpura (ITP) in Rh-positive patients.
Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
platinum
doublet therapy (a two-drug regimen that includes a
platinum derivative such as carboplatin ...
The FDA has approved the immune checkpoint
inhibitor atezolizumab (Tecentriq – Genentech) for
treatment of locally advanced or metastatic urothelial
carcinoma and metastatic non-small cell lung cancer
(NSCLC) that have progressed during or following
platinum-based chemotherapy. Atezolizumab is the
first programmed death-ligand 1 (PD-L1) blocking
antibody to become available in the US. Two other
immune checkpoint inhibitors, the programmed death
receptor-1 (PD-1) inhibitors nivolumab (Opdivo) and
pembrolizumab (Keytruda), are also approved for
treatment of metastatic NSCLC, and...